Hovione announced that it has expanded its continuous manufacturing offering and services. A new continuous manufacturing facility is now coming online at the Loures site in Portugal. In addition, the company has established a multi-disciplinary global team in continuous tableting and upgraded its labs with the tools needed to support the drug product lifecycle.
Continuous manufacturing is expected to change the landscape of drug product development and commercial production. The Food and Drug Administration (FDA) is partnering with the International Council for Harmonization and leading a global initiative to advance continuous manufacturing of small molecules and other pharmaceutical modalities.
Hovione is offering customers a commercial continuous tableting platform prepared to support key control needs and deliver on operational excellence, mechanistic modeling, and appropriate process analytical technology (PAT). Additionally, Hovione's system has been designed to support the release of continuous tableting products through automated in-process controls, deployment of real time release, and compliant digital infrastructure.